


HEPATITIS B IN THE UNITED STATES

First generation African communities: Why test now?



IF LEFT UNTREATED, up to **1 in 4 people** with chronic hepatitis B (CHB) develop liver problems such as cirrhosis and liver cancer¹




APPROXIMATELY **15% to 40%** of persons with CHB develop cirrhosis, HCC, or liver failure, which leads to substantial morbidity and mortality²



PERSONS WITH CHB:
• are **100x more likely** to develop liver cancer than uninfected persons³
– A 5-year cumulative risk of developing liver cancer in patients with cirrhosis is 5% to 30%³



• die an average of **22 years earlier** than uninfected persons⁴



>**80%** UNDIAGNOSED

More than 80% of persons **in the United States** with CHB are undiagnosed⁸

3 TESTS TO ORDER

A simple blood test, which is covered by most insurance, will look for^{9,10}:

- HBsAg** (hepatitis B surface antigen)
- anti-HBs** (hepatitis B surface antibody)
- anti-HBc** (hepatitis B core antibody)

To ensure reimbursement eligibility, confirm with patient's insurance coverage.

Test for hepatitis B

References: 1. Centers for Disease Control and Prevention. Hepatitis B questions and answers. CDC website. Updated April 7, 2021. Accessed June 13, 2022. <https://www.cdc.gov/knowhepatitis/faqs.htm> 2. US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020;324(23):2415-2422. 3. National Cancer Institute. National Institutes of Health, US Department of Health and Human Services. Liver (Hepatocellular) Cancer Prevention (PDQ®)—Health Professional Version. NCI website. Updated March 2, 2022. Accessed June 13, 2022. https://www.cancer.gov/types/liver/hp/liver-prevention-pdq#_177_toc 4. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. *Clin Infect Dis*. 2014;58(1):40-49. 5. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet*. 2015;386(10003):1546-1555. 6. Ndom P. Cancer prevention in Africa: liver cancer. *Ecanermedalscience*. 2019;13:950. doi:10.3332/ecancer.2019.950 7. Centers for Disease Control and Prevention. People born outside of the United States and viral hepatitis. CDC website. Updated September 24, 2020. Accessed June 13, 2022. <https://www.cdc.gov/hepatitis/populations/Born-Outside-United-states.htm#:~:text=During%20the%20past%203%20decades,12%25%20were%20born%20in%20Africa> 8. Ogawa E, Yeo YH, Dang N, et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. *JAMA Netw Open*. 2020;3(4):e201844. doi:10.1001/jamanetworkopen.2020.1844 9. Weinbaum CM, Most EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. *Hepatology*. 2009;49(suppl 5):S35-S44. 10. Centers for Disease Control and Prevention. Viral hepatitis preventive services coverage. CDC website. Updated May 5, 2020. Accessed June 13, 2022. <https://www.cdc.gov/nchhstp/highqualitycare/preventiveservices/hepatitis.html>



HEPBMD, the HEPBMD Logo, the Liver Icon, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc. ©2022 Gilead Sciences, Inc. All rights reserved. US-UNBP-1062 07/22

hepBMD™



Persons depicted are models used for illustrative purposes and are not actual patients.